Showing 5671-5680 of 6787 results for "".
- Special Report: An Overview of Coronavirus by Dr. Jonathan Kaplanhttps://practicaldermatology.com/news/special-report-an-overview-of-coronavirus-by-dr-jonathan-kaplan/2460306/Wash your hands, wipe down surfaces, don’t touch your face, and practice social distancing. If nothing else, that’s what you should take away from this coronavirus overview. But keep reading to learn important details about this epidemic. Such as, how we can make it end with less coll
- Neauvia’s Introduces Zaffiro, A Two-Part Solution to Skin Rejuvenationhttps://practicaldermatology.com/news/neuvias-introduces-zaffiro-a-two-part-solution-to-skin-rejuvenation/2460305/Neauvia introduced Zaffiro to the media at an event held in New York City’s Hudson Yards, featuring New York City dermatologist Amy Lewis, MD Launched in the US in late 2019, the Zaffiro device is a dual facial rejuve
- International Psoriasis Council Offers Guidance on Managing COVID-19 in People with Psoriasishttps://practicaldermatology.com/news/international-psoriasis-council-offers-guidance-on-managing-covid-19-in-people-with-psoriasis/2460302/Psoriasis patients diagnosed with COVID-19 (coronavirus disease) should immediately discontinue or postpone immunosuppressant medications, guidance from the International Psoriasis Council (IPC) states. The group cites current guidance from the European Dermatology Forum and the American Academy
- New from Lumenis: Meet the Stellar M22 Platformhttps://practicaldermatology.com/news/new-from-lumenis-meet-the-stellar-m22-platform/2460300/Lumenis Ltd. is launching the Stellar M22, a multi-application platform that builds on the heritage of the M22 by adding even more bells and whistles. The new Stellar M22 is now available in the USA and Europ
- Galderma Rolls Out New Consumer-Facing Rewards App, Plus Morehttps://practicaldermatology.com/news/galderma-rolls-out-new-consumer-facing-rewards-app-plus-more-1/2460296/Galderma is enhancing its aesthetic portfolio with digital enhancements to Aspire Galderma Rewards, an expansion of its U.S. salesforce plus a collaboration with ZO Skin Health. "We want to enable every customer and partner to build experiences on our leading platforms,&q
- Sciton Names New CEOhttps://practicaldermatology.com/news/sciton-names-new-ceo/2460292/Aaron Burton is Sciton Inc.’s new Chief Executive Officer. Aaron has spent the last eight years at Sciton growing the Aesthetic Sales Team, Women’s Health Group, International Sales Team and more recently operations in our World Head
- Dermatologists React to Threat of Coronavirus Pandemichttps://practicaldermatology.com/news/dermatologists-react-to-threat-of-coronavirus-pandemic/2460291/Reports about COVID-19 are causing many dermatologists to rethink their travel plans and update their office policy on the care of sick patients. The International Health Regulations Emergency Committee of the World Health Organization declared the outbreak a “public health emerge
- Cynosure's Four-Mode RF Microneedling Device Cleared for Marketinghttps://practicaldermatology.com/news/cynosures-four-mode-rf-microneedling-device-cleared-for-marketing/2460289/The U.S. Food and Drug Administration (FDA) cleared Cynosure’s Potenza, a four-mode radiofrequency (RF) microneedling device. The Potenza device comprises four modes (monopolar or bipolar, delivered at either 1 MHz
- BTL Files Suit Against Allergan, Alleges Misleading Advertisinghttps://practicaldermatology.com/news/btl-files-suit-against-allergan-alleges-misleading-advertising/2460288/In a new lawsuit filed this week, BTL Industries alleges that Allergan launched a wide-ranging false and misleading advertising campaign relating to BTL's EMSCULPT device for non-invasive muscle toning and body shaping. The suit alleges that Allergan's marketing, sales materials, and soci
- Business News: Lilly, Dermira Acquisition Completehttps://practicaldermatology.com/news/business-news-lilly-dermira-acquisition-complete/2460287/Eli Lilly and Company has completed its acquisition of Dermira, Inc. The acquisition expands Lilly's immunology pipeline with the addition of lebrikizumab, a novel, investigational, monoclonal antibody designed to bind IL-13 that is being evaluated in a Phase 3 clinical development